Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study

Resource type
Journal Article
Authors/contributors
Title
Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study
Abstract
Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ transplantation (SOT). Most PTLD cases are associated with Epstein–Barr virus (EBV) infection. The role of antiviral prophylaxis or rituximab therapy for ...
Publication
American Journal of Transplantation
Date
2021/07
Volume
21
Issue
7
Pages
2532
Accessed
6/7/22, 8:25 AM
Short Title
Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs)
Language
en
Library Catalog
Extra
Publisher: Wiley-Blackwell PMID: 33289340
Citation
Walti, L. N., Mugglin, C., Sidler, D., Mombelli, M., Manuel, O., Hirsch, H. H., Khanna, N., Mueller, N., Berger, C., Boggian, K., Garzoni, C., Neofytos, D., Delden, C. van, Hirzel, C., & Study (STCS), S. T. C. (2021). Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study. American Journal of Transplantation, 21(7), 2532. https://doi.org/10.1111/ajt.16423